HomeProductsBuilding BlocksHeterocyclic ScaffoldsThiazolesVenglustat
Chemical structure of CAS 1401090-53-6

Venglustat

CAS No.1401090-53-6
MDL No.MFCD28502073
MFC20H24FN3O2S
MW389.50
InChI KeyYFHRCLAKZBDRHN-MRXNPFEDSA-N
CUSTOM SYNTHESIS

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1401090-53-6
Product NameVenglustat

Biological Targets

UGCG

Associated Conditions

Tay-Sachs disease·Parkinsonism·Autosomal dominant polycystic kidney disease·Sandhoff disease·cystic kidney disease·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Venglustat Inhibits Protein N-Terminal Methyltransferase 1 in a Substrate-Competitive Manner.

Journal of medicinal chemistry • Vol. 65, Issue 18 • 2022
PMID: 36074125PMC: PMC9813856DOI: 10.1021/acs.jmedchem.2c01050

Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus.

The Journal of biological chemistry • Vol. 296 • 2021
PMID: 33639165PMC: PMC7904475DOI: 10.1016/j.jbc.2021.100470

Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3.

ACS chemical neuroscience • Vol. 11, Issue 20 • 2020
PMID: 33035424PMC: PMC7919060DOI: 10.1021/acschemneuro.0c00558

Developments in the treatment of Fabry disease.

Journal of inherited metabolic disease • Vol. 43, Issue 5 • 2020
PMID: 32083331PMC: PMC7540041DOI: 10.1002/jimd.12228

Documentation

Similar Products